Description

Caplacizumab is a humanized, bivalent, single-variable-domain immunoglobulin (nanobody) designed for targeted therapeutic intervention. This innovative compound functions as a specific inhibitor of von Willebrand factor (vWF), preventing the formation of ultra-large vWF multimers and subsequent platelet adhesion. It is primarily utilized in the pharmaceutical and biotechnology sectors for the development and manufacture of treatments for specific hematological disorders. The product is supplied under the identifier CAS NO 915810-67-2.

Application

• Primary Pharmaceutical Ingredient: Active pharmaceutical ingredient (API) in the formulation of treatments for acquired thrombotic thrombocytopenic purpura (aTTP).
• Biopharmaceutical Research: A critical tool in hematology and vascular biology research for studying vWF-platelet interactions and thrombus formation.
• Clinical Development: Used in the development and manufacturing of clinical trial materials for novel anti-thrombotic therapies.
• Precision Medicine: Serves as a targeted therapeutic agent for conditions characterized by abnormal microvascular thrombosis.
• Drug Discovery: A reference standard and lead compound in the discovery of next-generation nanobody-based therapeutics.

Basic Information

Product Name	Caplacizumab
CAS No.	915810-67-2
Molecular Formula	C2140H3284N568O660S12
Molecular Weight	Approx. 48,000 Da
Synonyms	ALX-0081; ALX0081; Anti-von Willebrand factor Nanobody; Caplacizumab-yhdp; Cablivi; Anti-vWF Nanobody; Bivalirudin Nanobody Analog; vWF Inhibitor Nanobody
EINECS	Contact for details

Quality Control

Our Caplacizumab is manufactured and controlled under strict quality systems. The product undergoes rigorous analytical testing to ensure identity, purity, potency, and safety, meeting standards suitable for pharmaceutical development. A comprehensive Certificate of Analysis (COA) is provided with each batch, detailing specifications for appearance, protein content, biological activity (vWF binding inhibition), purity by SE-HPLC and CE-SDS, and tests for host cell proteins, DNA, and endotoxins.

Storage

Preserve in a tightly closed container, protected from light. For long-term stability, store lyophilized powder at -20°C or below. Reconstituted or liquid formulations should be stored as directed in the specific product data sheet, typically at 2-8°C. Avoid repeated freeze-thaw cycles.

Specification

Item	Specification
Appearance	White to off-white lyophilized powder or clear solution
Identification (Mass Spec)	Conforms to standard
Protein Content (UV/A280)	≥ 95% of label claim
Purity (SE-HPLC)	≥ 98.0% Monomer
Purity (CE-SDS, reduced)	≥ 95.0%
Biological Activity (vWF binding assay)	Within specified range
Endotoxins (LAL)	< 1.0 EU/mg
Host Cell Proteins (ELISA)	< 100 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.